Cases & Investigations

Celebrex (Celecoxib) Antitrust Litigation

CASE NUMBER: 2:14-cv-00361
PRACTICE AREAS: Antitrust
PRODUCT: Anti-inflammatory drug Celebrex (celecoxib)
CASE STATUS: Settled
SETTLEMENT AMOUNT: $94 million
COURT: U.S. District Court for the Eastern District of Virginia

Berger Montague represented a class of direct purchasers of brand and generic Celebrex (celecoxib) in an action alleging that Pfizer, in violation of the Sherman Act, improperly obtained a patent for Celebrex from the U.S. Patent and Trademark Office in a scheme to unlawfully extend patent protection and delay market entry of generic versions of Celebrex. Plaintiffs alleged that Pfizer’s conduct caused the class overcharge damages.

After more than three years of litigation and on the eve of trial, the direct purchaser class settled with Pfizer. Pfizer agreed to pay $94,000,000 in the settlement.  The settlement was given final approval on April 18, 2018.

LEAD ATTORNEYS: David F. Sorensen, Ellen T. Noteware, Zachary D. Caplan

Lead Attorneys

David Sorensen Headshot

David F. Sorensen

Managing Shareholder
Ellen Noteware Headshot

Ellen T. Noteware

Shareholder

Request A Free Consultation

  • This field is for validation purposes and should be left unchanged.